Asep Medical Raises 5 Million RMB Through the Sale of a 10% Stake in Chinese Joint Venture

Following this transaction, Sepset retains a 15% ownership stake in SepSMART. This strategic investment by Sansure reflects a decisive vote of confidence in Sepset's sepsis diagnostic technology and provides additional capital to accelerate its development and commercialization in China and globally. SepSMART was established as a joint venture between Sepset Biosciences and Sansure Biotech to advance Sepset's rapid sepsis diagnostic test, known as SepsetER, in the Chinese market.

Dr. Robert E. W. Hancock, Asep Medical's Chair, CEO, and inventor of the Sepset technology, stated, "We are excited by Sansure's ongoing support of our vision. This investment provides essential resources to advance our Sepset diagnostic technology and will help push our efforts forward in the global fight against sepsis."

The CAD $964,000 capital injection will enable Sepset to accelerate its ongoing development programs and bring the SepsetER test closer to widespread clinical use, supporting Asep Medical's mission to combat sepsis worldwide.

Asep Medical is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists and the CEO of Asep. Asep holds a controlling interest in two private subsidiary companies - Sepset Biosciences (Asep's leading product, a

sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations cater to unmet medical needs, it offers a unique investment opportunity for retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

Sansure Biotech Inc., a listed company in China, is a comprehensive provider of integrated diagnosis and treatment solutions, with independent and innovative gene technology at its core. Founded in 2008, with Changsha and Shanghai as its strategic hubs, Sansure has further expanded its global presence and established more than 40 subsidiaries and branches across China and key global markets including the UK, France, the US, Indonesia, the Philippines, Thailand, and beyond. With over 40% of employees dedicated to R&D, the company has pioneered a series of leading core technologies and developed over 1,000 products, along with more than 2,200 kinds of high-quality testing services, covering reagent, instrument, quality control, technical training and service, independent clinical laboratory service, genetic testing service, biopharmaceutical, etc. These products and solutions are used by over 10,000 benchmark hospitals and laboratories worldwide, serving billions of people across over 160 countries and regions. With unwavering determination, Sansure will continue to advance its transformation into a world-class life sciences enterprise.

Chris Dallin

Asep Medical Holdings Inc.

E. chris@asepmedical.com

T. 604-362-3654

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the successful development, testing and commercialization of our sepsis diagnostic test (Sepset) and its intended regulatory filings; the Company not receiving regulatory market authorization as planned or at all; the undertaking of pre-clinical and clinical studies on our products, with the expectation that this will lead to regulatory approval; the timeframe for identification of sepsis with the Company's products; the potential opportunities for the generation of revenue; the anticipated benefits of the Company's

products; and other statements regarding the Company's proposed business plans. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks including the risk that the Company's products may not perform as expected; that the Company may not receive the requisite regulatory approvals or achieve the results of testing; the Company's testing of the products may not be successful and regulatory approval may not be obtained in the estimated timelines or at all; the Company may not be able to generate revenue from its products as expected or at all; the market for the Company's products may not be as described in this news release; and various other risk factors identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at https://www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.